Abstract 2137P
Background
Performance ECOG status and staging are described as prognostic factors in oncologic outpatients while nutritional assessment can impact survival in both outpatients and inpatients. The aim of this study was to describe the Charslon Comorbidity Index (CCI), the nutritional status, the impact of opioid therapy and psycho-oncology and palliative care unit intervention for hospitalized cancer patients (pts).
Methods
A prospective multicentric study of pts hospitalized between January 2020 February 2022 at Vall d’Hebron and Sant Pau Hospitals [Plantology database] in Spain. Demographic and clinical variables such as CCI, laboratory results and nutritional status were collected at admission. Prognostic Nutritional Index (PNI) was calculated at admission. Quality of life (QoL) was collected through the EORTC-QLQ30 v.3 questionnaire. Statistical analysis was performed with SPSS v.29 (Log rank, Chi-square, Student’s t-test were used).
Results
A total of 1.431 patients (median age 66 years, 53.2% males) were included with a median of 9 days hospitalized. With a follow-up of 15 months, the median survival was 4.67 months after admission. Most pts (91.6%) had severe comorbidity (CCI ≥ 5 points) related to a lower survival (4.5 vs 12.8 months, p<0.001). A positive chair stand test for sarcopenia (12.2%) was associated with reduced survival (3.5 vs 9.1 months, p<0.001). Pts with hypoalbuminemia (65.3%) presented lower survival (3.5 vs 8.4 months, p<0.001). In addition, the PNI stratified 59.5% pts with serious malnutrition (PNI <40) linked to reduced survival (3.6 vs 7.9 months, p<0.001). Regarding supportive care, pts under opioid therapy (39.6%) had a higher QoL (mean EORTC QLQ-30 score of 73.4 vs 64.3, p<0.001). Palliative care team assessment and psycho-oncology intervention positively impacted in pts QoL (EORTC QLQ-30 of 74 vs 67.3, p<0.001, and 74.3 vs 65.2, p<0.001, respectively).
Conclusions
In hospitalized cancer pts, severe comorbidity, malnutrition and sarcopenia were associated with a reduced survival. Opioid therapy and psycho-oncological and palliative care unit intervention had a positive impact on the QoL of pts. Early supportive care interventions are key to improve symptomatology and preserve QoL of hospitalized cancer pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
VHIO.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2173P - Exploring the complex needs of older patients receiving targeted therapies and immune checkpoint inhibitors for renal and skin cancers at the Royal Marsden Hospital
Presenter: Niamh Cunningham
Session: Poster session 07
2174P - The impact of exposure to antibiotic (ATB) and proton pump inhibitor (PPI) therapy on immune checkpoint inhibitor (ICI) treatment on overall survival (OS): A population-based study
Presenter: Lawson Eng
Session: Poster session 07
2175P - Sex and age-related differences in immunotherapy-induced toxicities
Presenter: Mafalda Teixeira da Costa
Session: Poster session 07
2176P - Rechallenge of immune checkpoint inhibitors after immune-related adverse events: A systematic review
Presenter: Jin Young Kim
Session: Poster session 07
2177P - Immunotherapy adverse events association with inflammation scores: A real-world data analysis from a Portuguese hospital
Presenter: Catarina Fernandes
Session: Poster session 07
2179P - Prospective monitoring of autoimmune events in cancer immunotherapy patients: A report on the first 658 patients in the PRAISE study
Presenter: Eden Sebbag
Session: Poster session 07
2180P - Detrimental effect of an early exposure to antibiotics on the outcomes of immunotherapy in a multi-tumor cohort of patients
Presenter: Víctor Albarrán
Session: Poster session 07
2181P - Effect of different corticosteroid treatment strategies on checkpoint inhibitors pneumonitis outcomes
Presenter: Hui Guo
Session: Poster session 07
2182P - Patient involvement to improve prospective follow-up: Quality of life data after cancer immunotherapy from the PRAISE study
Presenter: Eden Sebbag
Session: Poster session 07
2183P - The relevance of HFpEF in immunotherapy-induced myocarditis: An analysis of 65 patients
Presenter: Adam Chapman
Session: Poster session 07